NovImmune SA   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Geneva Switzerland (1998)
Status: Acquired by Swedish Orphan Biovitrum (2019) → now Advent International (2021)

Organization Overview

First Clinical Trial
2006
NCT00630643
First Marketed Drug
2018
emapalumab-lzsg (gamifant)
First NDA Approval
2018
emapalumab-lzsg (gamifant)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

LCB - Novimmune SA | Light Chain Bioscience - Novimmune SA | NovImmune SA | NOVIMMUNE S.A.

Active Ingredients

Marketed Drugs (1)

emapalumab-lzsg (gamifant) (2018 NDA)

Drugs in Phase 3 Trials (1)

emapalumab-lzsg (gamifant) (6 trials)

Drugs in Phase 2 Trials (3)

ni-0101 (1 trial)

ni-0401 (2 trials)

ni-0801 (2 trials)

Drugs in Phase 1 Trials (3)

cp-870893 (1 trial)

ni-0701 (1 trial)

ni-1801 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Juvenile (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Crohn Disease (Phase 2)

Dermatitis (Phase 1)

Dermatitis, Allergic Contact (Phase 1)

Dermatitis, Contact (Phase 1)

Fibrosis (Phase 2)

Liver Cirrhosis (Phase 2)

Liver Cirrhosis, Biliary (Phase 2)

Lymphohistiocytosis, Hemophagocytic (Phase 3)

Macrophage Activation Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 7